The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms
Amanda M. Buck; Amelia N. Deitchman; Saki Takahashi; Scott Lu; Sarah A. Goldberg; Aaron Bodansky; Andrew Kung; Rebecca Hoh; Meghann C. Williams; Marian Kerbleski...
Full title:
Investigating antibody reactivity to the intestinal microbiome in severe myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS)
Preprint
Abstract
Myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic disease of unknown aetiology that is characterised...
Abstract
Background Post-COVID19 complications such as pediatric inflammatory multisystem syndrome (PIMS) and Long-COVID19 move increasingly into focus, potentially causing more harm in this age group than the acute infection. To better understand the symptoms of long-COVID19 in adolescents and...
First Clinical Study of the Safety and Blood Levels of a Human Monoclonal Antibody (2217LS) Against Lyme Disease Bacteria in Healthy People, 2021, MassBiologics, Phase I
Study Type : Interventional (Clinical Trial)
Estimated Enrollment : 48 participants
Allocation: Randomized
Intervention...
Antibody for SARS -CoV- 2
https://www.biorxiv.org/content/10.1101/2020.03.11.987958v1.full.pdf+html
As I remember it an antibody can be used for passive immunisation to reduce deaths in infected individuals.
@Jonathan Edwards
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.